Research on Parkinson's disease and its treatment. Covers mitochondrial protection, genetic progression markers, antibody therapies, and disease costs.
Researchers discovered a protein imbalance in Parkinson's disease patients and found that adding a phosphate group can reduce toxicity. The study suggests alpha-synuclein protein plays a key role in brain cell communication and may be a potential target for therapy.
A new study by Buck Institute researchers finds that high levels of MAO-B enzyme in mice lead to Parkinson-like symptoms. The findings suggest that humans with high MAO-B levels may be at risk for the disease and could benefit from preventive treatment.
A study of 7,374 participants found that those taking calcium channel blockers for high blood pressure had a lower risk of developing Parkinson's disease. The medication was shown to cut the risk by 23% compared to non-users, but not other high blood pressure medications.
Researchers found that manipulating serotonin receptors can block L-DOPA-induced side effects in advanced Parkinson's disease. The discovery suggests a new approach for developing treatments for this disorder, which is the second most common neurodegenerative disease after Alzheimer's.
A new guideline from the American Academy of Neurology highlights individuals at risk of falling due to conditions like stroke, dementia, Parkinson's disease, and vision loss. Regular screening and preventive measures can help prevent fall-related injuries and deaths.
Researchers developed MAPAS to predict protein contact surfaces, which can guide new treatments for devastating diseases. The tool uses supercomputers to analyze protein shapes and energy, revealing key details of membrane interactions.
The Michael J. Fox Foundation has awarded up to $3 million in funding to four industry teams as part of its Therapeutics Development Initiative, focusing on treatments targeting alpha-synuclein toxicity, chronic inflammation, trophic factors, and mitochondrial dysfunction. The grants aim to accelerate the development and delivery of tr...
A new Mayo Clinic study identified several gene variations that predict people at high risk for ALS and Parkinson's disease. The researchers found a high-risk prediction factor for ALS (2,000 times greater than average) and for Parkinson's disease (nearly 400 times greater than average).
A new study found trichloroethylene to be a risk factor for parkinsonism, a group of nervous disorders with symptoms similar to Parkinson's disease. The study showed that chronic exposure to TCE can lead to degenerative changes in the brain, including reduced mitochondrial function and dopamine neuron damage.
A study by Einstein researchers suggests that impaired autophagy may contribute to the development of Parkinson's disease. The team found that dopamine-altered alpha-synuclein molecules interfere with lysosomal digestion, leading to toxic compound accumulation and cell death.
Researchers found that green tea polyphenols protect dopamine neurons and inhibit the ROS-NO pathway, which contributes to cell death in Parkinson's disease. The study suggests green tea polyphenols may be developed into a safe and easily administrable drug for Parkinson's disease treatment.
A recent study by Mayo Clinic found that relatives of patients with Parkinson's disease are at increased risk for developing depression and anxiety disorders. The risk is particularly elevated in families where the patient develops Parkinson's before age 75.
Researchers at Université Laval discovered that a diet rich in omega-3 fatty acids protects the brain against Parkinson's disease. The study found that mice fed an omega-3 rich diet were immune to the toxic compound MPTP, which causes damage to dopamine-producing neurons.
A recent study using PET scans shows that an experimental gene therapy can normalize brain function in Parkinson's patients. The treatment was found to alter brain activity in a favorable way, primarily affecting motor networks.
Regular use of non-aspirin NSAIDs reduced Parkinson's disease risk by up to 60% compared to non-users. Women who regularly used aspirin also showed a 40% reduced risk, especially after two years of use.
Researchers at Saint Louis University School of Medicine discovered a key brain chemical that causes Parkinson’s disease. They found that dopamine itself is converted into DOPAL, which triggers the death of dopamine-producing cells and leads to Parkinson’s.
Researchers found that Deep Brain Stimulation (DBS) actually speeds up decision-making in Parkinson's patients, contrary to expectations. The study suggests that DBS affects the brain's ability to deliberate on complicated decisions by interrupting the 'hold-your-horses' signal.
Research at The Parkinson's Institute and Clinical Center found that intermittent nicotine treatment reduces medication-induced dyskinesias in Parkinson's disease models. This could lead to more effective and long-term treatment options for patients suffering from the condition.
First-degree relatives of patients with Parkinson's disease are at increased risk of developing dementia and cognitive impairment, particularly those with younger age of onset. The study suggests shared familial susceptibility factors may be driving this association.
Researchers at ESRF and CNRS used chemical nano-imaging to visualize iron distribution in dopaminergic neurons. They found that iron is stored within dopamine vesicles, which helps explain the molecular mechanisms involved in Parkinson's disease.
Researchers analyzed genes of 278 people with Parkinson's disease and found a higher prevalence of mutations in the GBA gene among those diagnosed before age 50. The study suggests that Jewish ancestry may be an important risk factor for younger-onset Parkinson's disease due to the increased presence of GBA gene mutations in this group.
Researchers have created 'pro-chelators' that can selectively bind to potentially destructive forms of iron in the brain, reducing oxidative stress and cell damage associated with these diseases. The iron-binding agents are designed to target only harmful iron species, allowing benign forms to carry out vital functions.
Researchers found a link between the loss of norepinephrine and dopamine neurons and delayed Parkinson's symptoms. The study showed that both types of neurons are necessary for normal motor function.
A study published in BMC Medicine found that simvastatin is associated with a lower incidence of dementia and Parkinson's disease. The researchers analyzed data from over 700,000 simvastatin users and more than 50,000 atorvastatin users to confirm the benefits of simvastatin on these conditions.
Researchers found that transplanted stem cells triggered the brain's self-repair mechanisms by boosting nerve survival and blood vessel development. The study suggests that stem cells may be more effective at repairing damaged brain tissue than previously thought.
Researchers have identified two separate brain networks affected by Parkinson's disease, one regulating movement and the other cognitive function. The study found that standard treatments alter the motor network but not the cognitive network, highlighting the need for new treatments to target cognition.
Researchers identified risk factors for hallucinations, sleepiness and swelling in people with early Parkinson's disease, including being male, having multiple health problems and taking certain medications. The study found nearly half of participants developed swelling within four years of treatment.
A pooled analysis of data from previous studies suggests that cigarette smoking is associated with a reduced risk for developing Parkinson’s disease. Current and long-term smokers had the lowest risk, while those who quit smoking up to 25 years prior to diagnosis also showed a significant decrease in risk.
A recent study reveals that depression is common in early Parkinson's disease diagnosis, with 27% of subjects screening positive for depression. Untreated depression can significantly impact daily life activities and overall quality of life.
In mice and human patients, researchers found that crippling of protective enzyme Prx2 leads to death of dopamine-producing neurons in Parkinson's disease. Activating Prx2 prevents neuronal loss, suggesting it as a beneficial target for PD treatment.
Researchers at University of Helsinki discover novel neurotrophic factor CDNF that protects and rescues damaged dopamine neurons, recovering function after experimental lesion. This breakthrough may lead to new treatment strategies for Parkinson's disease.
The Parkinson's Institute has received a $1 million grant from the Valley Foundation to support its STOP PD program, which aims to identify compounds to halt Parkinson's disease progression. The new facility will enable expanded research and patient services, offering improved care for those diagnosed with Parkinson's.
The Penn Udall Center will focus on dementia and Parkinson's disease, with objectives including developing a new rating scale for activities of daily living and studying the neural basis of cognitive deficits in Parkinson's disease. The center aims to improve care and treatment for patients and train physicians.
A novel gene therapy technique has been found safe and effective in reducing worsening symptoms of Parkinson's disease in advanced patients. The treatment, which involves injecting genes into one side of the brain to restore a critical neurotransmitter called GABA, showed a 27% improvement in symptoms among participants.
A large-scale study found that high levels of urate in the blood are strongly associated with a reduced risk of Parkinson's disease. Urate, a normal component of blood, may have beneficial effects due to its antioxidant properties.
A new gene therapy clinical trial has reported promising results in improving motor function for patients with Parkinson's disease. The study found significant improvements in both the off-state and on-medication phases, with some patients showing impressive gains of up to 65 percent.
A Phase 1 study using an adeno-associated virus vector to deliver an inhibitory gene to the subthalamic nucleus demonstrated a lack of adverse events and statistically significant improvements in clinical symptoms and brain metabolism. The treated side showed notable improvement, with sustained benefits observed over 12 months.
A study published in The Lancet found that gene therapy can safely alleviate symptoms of Parkinson's disease, with significant improvements seen in movement and motor scores. The treatment involves injecting genetic information directly into brain cells, eliminating the need for indwelling hardware associated with deep-brain stimulation.
Scientists have discovered a potential new treatment for Parkinson's disease by inhibiting the action of an enzyme called SIRT2. Blocking this pathway is believed to protect neurons damaged in Parkinson's from the toxic effects of alpha-synuclein, a protein that accumulates in the brains of patients.
A novel signaling pathway has been identified as being altered by genetic mutations in Parkinson's disease, affecting cellular function and potentially leading to new therapeutic targets. The research found that mitochondrial protein PINK1 plays a crucial role in protecting cells from oxidative stress and promoting cell survival.
The study reveals a novel anti-apoptotic signaling pathway disrupted by PINK1 mutations, suggesting a potential target for therapeutic intervention in Parkinson's disease. Increasing evidence links single-copy mutations in PINK1 to the development of later-onset PD.
A new study from Mayo Clinic researchers reveals that the joint effects of common DNA variations in several genes within a well-defined biological pathway largely explain why some people develop Parkinson’s disease. The findings also predict with great accuracy at what age people might develop their first symptoms.
Researchers have found that Isradipine slows the destruction of dopamine-producing neurons in a mouse model, potentially preventing Parkinson's disease or slowing its progression. The study aims to develop clinical trials in humans to test the drug's efficacy.
Researchers from Yale University and others report that injecting human neural stem cells into primates with severe Parkinson's disease improved symptoms such as tremors and motor function. The study found that the stem cells survived, migrated, and had a functional impact, suggesting a potential therapeutic value.
Researchers at Northwestern University have discovered a drug that slows and may halt the progression of Parkinson's disease by rejuvenating aging dopamine cells. Isradipine, a widely used hypertension medication, restores stressed-out dopamine neurons to their youthful state, potentially extending the time L-DOPA works effectively.
A study found that exposure to pesticides increases the risk of Parkinson's disease, as does traumatic head injury, with higher levels of exposure associated with greater risk. The two factors are potentially modifiable, suggesting opportunities for prevention and reduction.
Researchers at Mayo Clinic have discovered a correlation between violent rapid eye movement sleep behavior disorder and eventual onset of parkinsonism or dementia. Patients with the disorder may be exhibiting early signs of an evolving neurodegenerative disease caused by abnormal synuclein protein clumps.
Scientists have successfully implanted dopamine generators in brain cells, leading to improved symptoms in Parkinson's disease in non-human primates. The treatment involves injecting fragments of the carotid body into the striate area of the brain, which boosts the production of dopaminergic cells and increases dopamine release.
A new study from USC researchers found that treadmill exercise can improve balance and stability in patients with Parkinson's Disease. The study, published in the Journal of Neuroscience, suggests that exercise may help the brain work more efficiently by allowing remaining dopamine-producing neurons to function harder.
A randomized clinical trial found that a 300-milligram dose of CoQ10 did not improve Parkinson's disease symptoms in patients. However, the treatment was well-tolerated and increased blood levels of CoQ10, suggesting potential benefits at higher doses.
Parkinson's disease and narcolepsy share symptoms due to damage in the same small group of neurons. Researchers found that Parkinson's patients have severe loss of hypocretin cells, which may be reversible with treatments aimed at reversing this deficit.
Researchers found people taking antidepressant medications were nearly twice as likely to develop Parkinson's disease than those not taking the medication. Depression was identified as an early symptom of Parkinson's, appearing in the year before diagnosis.
Researchers found people taking levodopa were 95% more likely to choose symbols associated with higher monetary gains than those on haloperidol. Dopamine depletion may lead to lack of motivation in Parkinson's disease patients.
Researchers are developing nanotechnology to stimulate the body's healing abilities, enabling damaged organs to repair themselves. Early results show paralyzed lab mice regaining mobility after receiving a nanomaterial injection, offering hope for treating intractable diseases.
Research found that individuals with moderate to vigorous exercise levels were 40% less likely to develop Parkinson's disease than those with low activity levels. The study of over 143,000 people suggested a potential benefit of regular physical activity in reducing the risk of this debilitating condition.
A novel video-imaging system reveals that slow component-b proteins, involved in Parkinson's and Alzheimer's diseases, exhibit rapid bursts of movement followed by pauses. Multiple slow proteins are also transported together as 'packets,' piggy-backing on molecular motors, suggesting a potential carpooling mechanism.
Research reveals a strong link between stroke damage to brain region putamen and motor neglect, a condition causing slow movement on the left side. Treatment targeting dopamine-like compounds may ease this disability in patients with Parkinson's disease.
A study found that people who smoked and drank coffee were less likely to develop Parkinson's disease, which may be due to genetic or environmental factors. However, the risks of smoking and caffeine consumption should not be taken to avoid the disease.
Individuals with Parkinson's disease are less likely to smoke or consume high doses of caffeine than their family members. Smoking, caffeine consumption, and NSAID use were found to be inversely associated with Parkinson's disease, with no link between NSAID use observed.
Research highlights the role of pesticides, toxic agents, and inflammation in Parkinson's development, while also exploring potential neuroprotective agents like nicotine. The findings aim to better understand the disease process and develop preventive measures.